Electrochemotherapy for disseminated superficial metastases from malignant melanoma

The aim of the study was to determine predictive factors for effectiveness, toxicity and local disease control in patients with malignant melanoma treated with bleomycin‐based electrochemotherapy (ECT).

[1]  L. Mir,et al.  Antitumor electrochemotherapy: New advances in the clinical protocol , 1996, Cancer.

[2]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[3]  J. Thomas,et al.  Management of in‐transit metastases from cutaneous malignant melanoma , 2004, The British journal of surgery.

[4]  P. Hersey,et al.  Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy) , 2005, Melanoma research.

[5]  M J Jaroszeski,et al.  Novel electrode designs for electrochemotherapy. , 1997, Biochimica et biophysica acta.

[6]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[7]  F. Ferris,et al.  Palliative wound care: managing chronic wounds across life's continuum: a consensus statement from the International Palliative Wound Care Initiative. , 2007, Journal of palliative medicine.

[8]  J. Grob,et al.  Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma , 2006, Journal of cutaneous medicine and surgery.

[9]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Kemény,et al.  Electrochemotherapy of cutaneous metastases of melanoma--a case series study and systematic review of the evidence. , 2011, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[11]  Damijan Miklavčič,et al.  Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy , 2006 .

[12]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[13]  M Cemazar,et al.  Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. , 2000, International journal of radiation oncology, biology, physics.

[14]  D. Miklavcic,et al.  Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. , 1998, British Journal of Cancer.

[15]  D Miklavcic,et al.  Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases , 2000, Melanoma research.

[16]  L. Mir,et al.  Electrochemotherapy, a new antitumor treatment. First clinical phase I‐II trial , 1993, Cancer.

[17]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[18]  Antonella Vecchiato,et al.  Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution’s Experience with 52 Patients , 2008, Annals of Surgical Oncology.

[19]  Damijan Miklavčič,et al.  Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study , 2006 .

[20]  S. Mocellin,et al.  Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases , 2010, Annals of Surgical Oncology.

[21]  C. Collins,et al.  Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes , 2006 .

[22]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[23]  W. Hohenberger,et al.  Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. , 1999, International journal of radiation oncology, biology, physics.

[24]  H. Kroon,et al.  Isolated limb infusion: A review , 2009, Journal of surgical oncology.

[25]  S. Orlowski,et al.  Mechanisms of electrochemotherapy. , 1999, Advanced drug delivery reviews.

[26]  Damijan Miklavcic,et al.  Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases , 2010, Expert review of anticancer therapy.

[27]  M. Tangney,et al.  Electrochemotherapy: Aspects of Preclinical Development and Early Clinical Experience , 2007, Annals of surgery.

[28]  M. Rols,et al.  Electrochemotherapy of cutaneous metastases in malignant melanoma , 2000, Melanoma research.

[29]  Laurence Zitvogel,et al.  Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses , 2008, Cancer Immunology, Immunotherapy.